The FDA has approved ICLUSIG® (ponatinib), the first and only kinase inhibitor in combination with chemotherapy indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Read More. 

Full prescribing information for ICLUSIG® will be posted here.

To learn more about ICLUSIG, please visit www.iclusig.com/hcp.